Antisense oligonucleotides (AONs) mediated exon skipping restored dystrophin in DMD patients after intramuscular and systemic delivery with two independent chemistries and the morpholino compound has recently received accelerated approval by the FDA16–20. Here, DMD is linked to Duchenne muscular dystrophy.